EGFR and lung cancer: In Chinese patients, 40% of lung cancer patients have epidermal growth factor receptor (EGFR) gene mutations, compared with only 15% in European patients, and these EGFR mutations confer sensitivity to tyrosine kinase inhibitors (TKIs) (4, 5).